Acquired resistance to anti-EGFR mAb ICR62 in cancer cells is accompanied by an increased EGFR expression, HER-2/HER-3 signalling and sensitivity to pan HER blockers

BACKGROUND: The human epidermal growth factor receptor (EGFR) is an important target for cancer treatment. Currently, only the EGFR antibodies cetuximab and panitumumab are approved for the treatment of patients with colorectal cancer. However, a major clinical challenge is a short-term response owi...

Descripción completa

Detalles Bibliográficos
Autores principales: Khelwatty, Said A, Essapen, Sharadah, Seddon, Alan M, Fan, Zhen, Modjtahedi, Helmout
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2015
Materias:
Translational Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4651123/
https://www.ncbi.nlm.nih.gov/pubmed/26372697
http://dx.doi.org/10.1038/bjc.2015.319

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4651123/
https://www.ncbi.nlm.nih.gov/pubmed/26372697
http://dx.doi.org/10.1038/bjc.2015.319

Ejemplares similares